Tissue and stool microbiome in pediatric inflammatory bowel disease patients: diversity differs in patients with relapsing and non-relapsing Crohn’s disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00083018" target="_blank" >RIV/65269705:_____/25:00083018 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00142797

Výsledek na webu

<a href="https://link.springer.com/article/10.1186/s13099-025-00766-5" target="_blank" >https://link.springer.com/article/10.1186/s13099-025-00766-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13099-025-00766-5" target="_blank" >10.1186/s13099-025-00766-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Tissue and stool microbiome in pediatric inflammatory bowel disease patients: diversity differs in patients with relapsing and non-relapsing Crohn’s disease

Popis výsledku v původním jazyce

Background: Inflammatory bowel diseases (IBD), including Crohn&apos;s disease (CD) and ulcerative colitis (UC), are chronic conditions characterized by periods of clinical remission and relapse. Pediatric cases (pIBD) often have a more complicated disease course, where approximately 30% will develop a relapse within a year of diagnosis. Identifying prognostic markers for pIBD is important to optimize treatment and improve long-term outcomes. Our aim was to analyze the tissue microbiome, identify microbial prognostic markers, and validate their predictive power in non-invasive fecal samples. Results: Tissue and fecal microbiome were characterized from a prospective cohort comprising 33 therapeutically naïve pCD and 23 pUC patients, and 26 non-IBD pediatric controls, using amplicon 16S rRNA gene sequencing. Disease relapse was monitored for one year. At diagnosis, relapsing pCD patients exhibited a significantly decreased alpha diversity and altered beta diversity in tissue compared to non-relapsing pCD patients. Specific taxa were differentially abundant in relapsing pCD, with Barnesiella being the most depleted genus in tissue samples. Receiver Operating Characteristic (ROC) analysis identified Barnesiella (AUC = 0.818), Butyricimonas, and Collinsella as individual microbial tissue markers discriminating pCD relapse. Combining Barnesiella with the weighted Pediatric Crohn&apos;s Disease Activity Index (wPCDAI) further enhanced the specificity and sensitivity of the ROC analysis (AUC = 0.872 in tissue, 0.852 in feces), suggesting potential for non-invasive prognostic markers from stool. Conclusions: Tissue and fecal microbial markers can predict relapse in pCD patients with high prognostic power, providing a basis for precision medicine and personalized treatment strategies in pIBD.

Název v anglickém jazyce

Tissue and stool microbiome in pediatric inflammatory bowel disease patients: diversity differs in patients with relapsing and non-relapsing Crohn’s disease

Popis výsledku anglicky

Background: Inflammatory bowel diseases (IBD), including Crohn&apos;s disease (CD) and ulcerative colitis (UC), are chronic conditions characterized by periods of clinical remission and relapse. Pediatric cases (pIBD) often have a more complicated disease course, where approximately 30% will develop a relapse within a year of diagnosis. Identifying prognostic markers for pIBD is important to optimize treatment and improve long-term outcomes. Our aim was to analyze the tissue microbiome, identify microbial prognostic markers, and validate their predictive power in non-invasive fecal samples. Results: Tissue and fecal microbiome were characterized from a prospective cohort comprising 33 therapeutically naïve pCD and 23 pUC patients, and 26 non-IBD pediatric controls, using amplicon 16S rRNA gene sequencing. Disease relapse was monitored for one year. At diagnosis, relapsing pCD patients exhibited a significantly decreased alpha diversity and altered beta diversity in tissue compared to non-relapsing pCD patients. Specific taxa were differentially abundant in relapsing pCD, with Barnesiella being the most depleted genus in tissue samples. Receiver Operating Characteristic (ROC) analysis identified Barnesiella (AUC = 0.818), Butyricimonas, and Collinsella as individual microbial tissue markers discriminating pCD relapse. Combining Barnesiella with the weighted Pediatric Crohn&apos;s Disease Activity Index (wPCDAI) further enhanced the specificity and sensitivity of the ROC analysis (AUC = 0.872 in tissue, 0.852 in feces), suggesting potential for non-invasive prognostic markers from stool. Conclusions: Tissue and fecal microbial markers can predict relapse in pCD patients with high prognostic power, providing a basis for precision medicine and personalized treatment strategies in pIBD.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30109 - Pathology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Gut Pathogens

ISSN

1757-4749

e-ISSN

1757-4749

Svazek periodika

17

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

90

Kód UT WoS článku

001616404200001

EID výsledku v databázi Scopus

2-s2.0-105021936302